# Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

> **NCT06964906** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 140 (estimated)

## Conditions studied

- ER+/HER2- Breast Cancer

## Interventions

- **PROCEDURE:** HIFU
- **DRUG:** Toripalimab
- **DRUG:** nab-Paclitaxel (nab-P)
- **DRUG:** Epirubicin (E)
- **DRUG:** Cyclophosphamide (C)

## Key facts

- **NCT ID:** NCT06964906
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-04
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06964906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06964906, "Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06964906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*